Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lowered its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 4.4% during the fourth quarter, Holdings Channel reports. The firm owned 34,578 shares of the company’s stock after selling 1,590 shares during the period. Mutual of America Capital Management LLC’s holdings in Axsome Therapeutics were worth $2,752,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. AQR Capital Management LLC increased its holdings in shares of Axsome Therapeutics by 1.7% in the 1st quarter. AQR Capital Management LLC now owns 8,825 shares of the company’s stock valued at $544,000 after acquiring an additional 148 shares during the period. Tower Research Capital LLC TRC increased its holdings in shares of Axsome Therapeutics by 21.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 993 shares of the company’s stock valued at $71,000 after acquiring an additional 178 shares during the period. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Axsome Therapeutics by 1.1% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 18,734 shares of the company’s stock valued at $1,309,000 after acquiring an additional 197 shares during the period. Fifth Third Bancorp increased its holdings in shares of Axsome Therapeutics by 100.0% in the 3rd quarter. Fifth Third Bancorp now owns 400 shares of the company’s stock valued at $28,000 after acquiring an additional 200 shares during the period. Finally, Rafferty Asset Management LLC increased its holdings in shares of Axsome Therapeutics by 4.7% in the 3rd quarter. Rafferty Asset Management LLC now owns 4,560 shares of the company’s stock valued at $319,000 after acquiring an additional 205 shares during the period. 81.49% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Axsome Therapeutics news, Director Roger Jeffs sold 29,976 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the sale, the director now directly owns 120,756 shares in the company, valued at approximately $8,416,693.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, COO Mark L. Jacobson sold 24,662 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total value of $1,904,892.88. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Roger Jeffs sold 29,976 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the completion of the sale, the director now owns 120,756 shares in the company, valued at $8,416,693.20. The disclosure for this sale can be found here. Insiders own 24.50% of the company’s stock.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $65.72 on Friday. The firm has a market capitalization of $3.11 billion, a P/E ratio of -12.64 and a beta of 1.13. Axsome Therapeutics, Inc. has a one year low of $55.02 and a one year high of $98.40. The company’s fifty day moving average is $78.69 and its two-hundred day moving average is $75.10. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.52 and a current ratio of 3.63.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Tuesday, February 20th. The company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($1.21) by $0.48. The company had revenue of $71.53 million for the quarter, compared to analyst estimates of $70.38 million. Axsome Therapeutics had a negative net margin of 88.41% and a negative return on equity of 70.67%. Analysts forecast that Axsome Therapeutics, Inc. will post -3.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 target price on shares of Axsome Therapeutics in a report on Tuesday, April 2nd. Guggenheim lifted their target price on shares of Axsome Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, February 21st. Piper Sandler boosted their price objective on shares of Axsome Therapeutics from $90.00 to $113.00 and gave the company an “overweight” rating in a research note on Tuesday, January 16th. Truist Financial reissued a “buy” rating and issued a $150.00 price objective on shares of Axsome Therapeutics in a research note on Tuesday, March 26th. Finally, Mizuho boosted their price objective on shares of Axsome Therapeutics from $108.00 to $109.00 and gave the company a “buy” rating in a research note on Thursday, March 28th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $119.67.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.